Aeriant Therapeutics AB
PrivateCompany Overview
Aeriant Therapeutics AB is a biotechnology company that develops novel, disease-modifying inhaled therapies for respiratory diseases such as COPD.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
chronic obstructive pulmonary diseaseCOPDinhaled therapysmall molecule drugrespiratory drugbiotechdrug discoveryclinical-stage biotechsmall airway diseasebronchodilatoranti-inflammatorypharma licensingdrug pipelinerespiratory medicine
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Aeriant Therapeutics AB Comparables
Compare Aeriant Therapeutics AB with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Arcede Pharma | 96% | |
| Aer Therapeutics | 78% | |
| Merck & Co., Inc. | 77% | |
Aeriant Therapeutics AB Funding Rounds
Historical fundraising activity
Aeriant Therapeutics AB Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Aeriant Therapeutics AB's valuation, stock price, and market status.
See something wrong or outdated?